SCHEMBL4865136

SCHEMBL4865136

CCC(COC)Nc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 3/20 0.56
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
HTT P42858 1/20 0.56
PDE5A O76074 1/20 0.54
LATS1 O95835 1/20 0.52
LATS2 Q9NRM7 1/20 0.52
GBA1 P04062 3/20 0.52
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
ABCG2 Q9UNQ0 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50
TSHR P16473 2/20 0.50
CYP2C19 P33261 2/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868040 0.89 ACP1 (0.70) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL4865087 0.80 MAPT (0.42) ALDH1A1MEN1MAPTKMT2AGBA1
SCHEMBL4866926 0.80 ACP1 (0.73) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL11247112 0.77 LDHA (0.58) ALDH1A1MEN1MAPTKMT2AHTT
SCHEMBL1083759 0.76 ACP1 (1.00) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL1084153 0.76 CYP1A2 (0.79) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL13309927 0.75 ADORA1 (0.53) ALDH1A1MEN1MAPTKMT2AHTT
SCHEMBL5103626 0.73 ACP1 (0.71) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL4889107 0.73 ACP1 (0.71) ACP1ALDH1A1MEN1MAPTKMT2A
SCHEMBL5103688 0.72 KMT2A (1.00) ACP1ALDH1A1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R ACP1 3203/4885ALDH1A1 2625/4885MEN1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.